Rita Scarpelli

Rita Scarpelli

Auto-generated profile, based on publicly available information

Rita Scarpelli

Medicinal Chemistry and Technologies for Drug Discovery and Delivery Facility, Istituto Italiano di Tecnologia, via Morego 30, 16163 Genova, Italy

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2016 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
MMMarco Migliore
Marco Migliore
SPSilvia Pontis
Silvia Pontis
AAAngel Luis Fuentes de Arriba
Angel Luis Fuentes de Arriba
NRNatalia Realini
Natalia Realini
ETEsther Torrente
Esther Torrente
DPDaniele Piomelli
Daniele Piomelli
Palmitoylethanolamide (PEA) and oleoylethanolamide (OEA) are endogenous lipid mediators that suppress inflammation. Their actions are terminated by the intracellular cysteine amidase, N‐acylethanolamine acid amidase (NAAA). Even though NAAA may offer a new target for anti‐inflammatory therapy, the lipid‐like structures and reactive warheads of current NAAA inhibitors limit the use of these agents as oral drugs. A series of novel benzothiazole–piperazine derivatives that inhibit NAAA in a potent and selective manner by a non‐covalent mechanism are described. A prototype member of this class (8) displays high oral bioavailability, access to the central nervous system (CNS), and strong activity in a mouse model of multiple sclerosis (MS). This compound exemplifies a second generation of non‐covalent NAAA inhibitors that may be useful in the treatment of MS and other chronic CNS disorders.

1 February 2016 in European Journal of Medicinal Chemistry
Verified
Journal Article
Open access
MMMarco Migliore
Marco Migliore
DHDamien Habrant
Damien Habrant
OSOscar Sasso
Oscar Sasso
CAClara Albani
Clara Albani
SBSine Mandrup Bertozzi
Sine Mandrup Bertozzi
RSRita Scarpelli
Rita Scarpelli
Non-steroidal anti-inflammatory drugs (NSAIDs) exert their pharmacological effects by inhibiting cyclooxygenase (COX)-1 and COX-2. Though widely prescribed for pain and inflammation, these agents have limited utility in chronic diseases due to serious mechanism-based adverse events such as gastrointestinal damage. Concomitant blockade of fatty acid amide hydrolase (FAAH) enhances the therapeutic effects of the NSAIDs while attenuating their propensity to cause gastrointestinal injury. This favorable interaction is attributed to the accumulation of protective FAAH substrates, such as the endocannabinoid anandamide, and suggests that agents simultaneously targeting COX and FAAH might provide an innovative strategy to combat pain and inflammation with reduced side effects. Here, we describe the rational design and structure-active relationship (SAR) properties of the first class of potent multitarget FAAH-COX inhibitors. A focused SAR exploration around the prototype 10r (ARN2508) led to the identification of achiral (18b) as well as racemic (29a-c and 29e) analogs. Absolute configurational assignment and pharmacological evaluation of single enantiomers of 10r are also presented. (S)-(+)-10r is the first highly potent and selective chiral inhibitor of FAAH-COX with marked in vivo activity, and represents a promising lead to discover novel analgesics and anti-inflammatory drugs.

23 July 2015 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ETEsther Torrente
Esther Torrente
CPChiara Parodi
Chiara Parodi
LELuisa Ercolani
Luisa Ercolani
CMClaudia De Mei
Claudia De Mei
AFAlessio Ferrari
Alessio Ferrari
Benedetto GrimaldiBenedetto Grimaldi
Benedetto Grimaldi

8 December 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
SCSamantha Caputo
Samantha Caputo
SMSimona Di Martino
Simona Di Martino
VCVincenzo Cilibrasi
Vincenzo Cilibrasi
PTPiero Tardia
Piero Tardia
MMMarco Mazzonna
Marco Mazzonna
RSRita Scarpelli
Rita Scarpelli
Acid ceramidase (AC) is a cysteine hydrolase that plays a crucial role in the metabolism of lysosomal ceramides, important members of the sphingolipid family, a diversified class of bioactive molecules that mediate many biological processes ranging from cell structural integrity, signaling, and cell proliferation to cell death. In the effort to expand the structural diversity of the existing collection of AC inhibitors, a novel class of substituted oxazol-2-one-3-carboxamides were designed and synthesized. Herein, we present the chemical optimization of our initial hits, 2-oxo-4-phenyl-N-(4-phenylbutyl)oxazole-3-carboxamide 8a and 2-oxo-5-phenyl-N-(4-phenylbutyl)oxazole-3-carboxamide 12a, which resulted in the identification of 5-[4-fluoro-2-(1-methyl-4-piperidyl)phenyl]-2-oxo-N-pentyl-oxazole-3-carboxamide 32b as a potent AC inhibitor with optimal physicochemical and metabolic properties, showing target engagement in human neuroblastoma SH-SY5Y cells and a desirable pharmacokinetic profile in mice, following intravenous and oral administration. 32b enriches the arsenal of promising lead compounds that may therefore act as useful pharmacological tools for investigating the potential therapeutic effects of AC inhibition in relevant sphingolipid-mediated disorders.

16 March 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
SMSimona Di Martino
Simona Di Martino
PTPiero Tardia
Piero Tardia
VCVincenzo Cilibrasi
Vincenzo Cilibrasi
SCSamantha Caputo
Samantha Caputo
MMMarco Mazzonna
Marco Mazzonna
RSRita Scarpelli
Rita Scarpelli
Sphingolipids (SphLs) are a diverse class of molecules that are regulated by a complex network of enzymatic pathways. A disturbance in these pathways leads to lipid accumulation and initiation of several SphL- related disorders. Acid ceramidase is one of the key enzymes that regulate the metabolism of ceramides and glycosphingolipids, which are important members of the SphL family. Herein, we describe the lead optimization studies of benzoxazolone carboxamides resulting in piperidine 22m, where we demonstrated target engagement in two animal models of neuropathic lysosomal storage diseases (LSDs), Gaucher’s and Krabbe’s diseases. After daily intraperitoneal administration at 90 mg Kg-1, 22m significantly reduced the brain levels of the toxic lipids glucosylsphingosine (GluSph) in 4L;C* mice and galactosylsphingosine (GalSph) in Twitcher mice. We believe that 22m is a lead molecule that can be further developed for the correction of severe neurological LSDs, where GluSph or GalSph play a significant role in disease pathogenesis.

1 January 2010 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
RSRita Scarpelli
Rita Scarpelli
JBJulia K. Boueres
Julia K. Boueres
MCMauro Cerretani
Mauro Cerretani
FFFederica Ferrigno
Federica Ferrigno
JOJesus M. Ontoria
Jesus M. Ontoria
PJPhilip Jones
Philip Jones